Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA Buys Serono, Gaining U.S. Commercial Organization

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck acquires family-owned shares representing 64.5% of Serono's capital and will launch a tender offer for the remainder, at a total value of $13.27 bil.

You may also be interested in...



Wealthy Families Play A Growing Role in European Biotech Financing

The continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.

Wealthy Families Play A Growing Role in European Biotech Financing

The continued dearth of venture capital in Europe is highlighting the key role played by wealthy families as an alternative – or at least complementary – source of finance for biopharmaceutical firms.

PML Reported In Raptiva User; Genentech Sends “Dear Doctor” Letter

Finding follows reports of PML in Rituxan, Tysabri patients earlier this year.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS064901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel